Thursday, September 10, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 27, 2025

Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035

View original at globenewswire.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 Ottawa, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Generic/biosimilar ADCs are the fastest growing drug type segment

    80% confidence

  • North America holds 55% revenue share of ADC market in 2024

    80% confidence

  • Cytotoxic payloads represent 70% of ADC payload market share in 2024

    80% confidence

  • Global antitumor ADC drugs market will grow from $8.33B in 2026 to $24.75B in 2035 at 12.86% CAGR

    80% confidence

  • Solid tumors represent the fastest growing therapeutic area for ADCs

    80% confidence

  • Hematologic cancers represent 35% of ADC therapeutic area market in 2024

    80% confidence

  • IV route accounts for 90% of ADC administration in 2024

    80% confidence

  • Asia-Pacific is the fastest growing ADC market region

    80% confidence

  • Branded ADC drugs represent 75% market share in 2024

    80% confidence

  • Hospital pharmacies and oncology centers represent 70% of ADC distribution in 2024

    80% confidence

  • Cleavable linkers represent 60% of ADC linker market share in 2024

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Boom Meets Valuation Jitters: Funding Surges While Bellwether Stocks Wobble
A dense wave of AI-sector funding (Socure, Stability AI, Emerald AI, Generalist AI, Gatik, Regent Craft and others closing rounds on the same day) and strong enterprise-automation earnings (UiPath raising full-year guidance) point to continued heavy capital deployment into AI infrastructure, fintech-adjacent AI, and agentic automation. Yet Palantir's stock fell even after winning the Army's high-profile TITAN contract, and commentary (e.g., the Alphabet bull case citing AI capex and regulatory risk) signals growing investor unease about whether current AI valuations and spending levels are sustainable.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts represent the same entity (JPMorgan Chase & Co.), same attribute (EPS), and same observation date (2025-12-31), which aligns with FY 2025 year-end reporting. Fact A explicitly states FY 2025 with EPS of 20.02 USD/share. Fact B has an unspecified fiscal period (N/A) but reports 4.63 USD, a significantly different value (4.3x lower). Given identical observation dates and the same metric, both facts appear intended to represent FY 2025 annual EPS. The conflicting values (20.02 vs 4.63) constitute a direct contradiction. The N/A period in Fact B suggests incomplete or corrupted metadata rather than legitimate time-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,278 source documents archived
Query this data → isubstrate.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 — Source | Via News | Via News